Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy

被引：0
|
作者：
Oh, H. -J. [1 ,2 ]
Park, C. -K. [1 ,2 ]
Kim, Y. -C. [1 ,2 ]
Kim, Y. -H. [1 ,2 ]
Ahn, S. -J. [1 ,2 ]
Jeong, W. G. [1 ,2 ]
Lee, J. Y. [1 ,2 ]
Lee, J. C. [3 ]
Choi, C. M. [3 ]
Ji, W. [3 ]
Song, S. Y. [3 ]
Choi, J. [3 ,4 ]
Lee, S. Y. [4 ,5 ]
Kim, H. [4 ]
Lee, S. Y. [4 ,5 ]
Park, J. [5 ]
Yoon, S. H. [6 ]
Joo, J. H. [6 ]
Oh, I. -J. [1 ,2 ]
机构：
[1] Chonnam Natl Univ, Sch Med, Jeonnam, South Korea
[2] Hwasun Hosp, Jeonnam, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Cenc, Seoul, South Korea
[4] Korea Univ, Coll Med, Guro Hosp, Seoul, South Korea
[5] Kyungpook Natl Univ, Sch Med, Daegu, South Korea
[6] Pusan Natl Univ, Sch Med, Yangsan Hosp, Gyeongnam, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
real-world data; chemoradiotherapy; durvalumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.28-12
引用
收藏
页码：S294 / S295
页数：2
相关论文
共 50 条
  • [31] Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
    Arunachalam, A.
    Vasudevan, A.
    Sura, S.
    Murphy, J.
    Goldschmidt, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S264 - S265
  • [32] Effect of durvalumab in patients with unresectable stage 3 non-small cell lung cancer post-chemoradiotherapy.
    Thurlapati, Aswani
    Dhaliwal, Lovekirat Singh
    Chennapragada, Sumasri
    Gutta, Pranavteja
    Song, Diana
    Ralla, Deepika
    Comeau, Jill
    Shi, Runhua
    Beedupalli, Kavitha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer
    Arunachalam, Ashwini
    Sura, Sneha
    Murphy, John
    Conkling, Paul
    Goldschmidt, Jerome
    PLOS ONE, 2024, 19 (11):
  • [34] Clinical outcomes in patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC) treated with durvalumab after chemoradiation in the United Kingdom: CODAK real-world study (NCT04667312)
    Franks, Kevin
    Smith, Daniel
    Shaw, Paul
    Banna, Giuseppe Luigi
    Cominos, Mathilda
    Talbot, Toby
    Blak, Betina T.
    Lindqvist-Brown, Linnea
    Ahmed, Merina
    LUNG CANCER, 2024, 190
  • [35] Real-world treatment patterns and outcomes among unresectable Stage III Non-Small Cell Lung Cancer
    Arunachalam, Ashwini
    Sura, Sneha
    Murphy, John
    Conkling, Paul
    Goldschmidt, Jerome
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E13 - E13
  • [36] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Christoph, D. C.
    Behringer, D.
    Emde, T. O.
    Goekkurt, E.
    Laack, E.
    Mueller-Huesmann, H.
    Schuett, P.
    Schumann, C.
    Seese, B.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
  • [37] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Girard, N.
    Mornex, F.
    Christoph, D. C.
    Fietkau, R.
    Filippi, A. R.
    Field, J.
    Garrido Lopez, P.
    McDonald, F.
    Peters, S.
    Klein, A. B.
    Licour, M.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1919 - 1929
  • [39] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Kim, Young-Hak
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 989 - 990
  • [40] Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
    Haratani, Koji
    Nakamura, Atsushi
    Mamesaya, Nobuaki
    Sawa, Kenji
    Shiraishi, Yoshimasa
    Saito, Ryota
    Tanizaki, Junko
    Tamura, Yosuke
    Hata, Akito
    Tsuruno, Kosuke
    Sakamoto, Tomohiro
    Teraoka, Shunsuke
    Oki, Masahide
    Watanabe, Hiroshi
    Tokito, Takaaki
    Nagata, Kenji
    Masuda, Takeshi
    Nakamura, Yasushi
    Sakai, Kazuko
    Chiba, Yasutaka
    Ito, Akihiko
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    BRITISH JOURNAL OF CANCER, 2024, 130 (11) : 1783 - 1794
12345